|Vol.1 Issue 5||gman.myeloma.org||September 2015|
GMAN Discussion Group Upgrade
As of August 18th, the web portal forum feature has been upgraded to support Google groups to allow for easier access and use. The new Google group, which allows members to sign in using their own email and password, has already seen an increase in discussion topics. Access to the forum can be found in the drop-down menu for “Member Portal” on the GMAN main page. If you have not received an invitation to join the Google group, please email Ray Wezik at firstname.lastname@example.org.
New Drug Launches in Bulgaria
On August 11th, Alvogen announced its launch of the first generic version of the cancer drug Velcade (Bortezomib) in Bulgaria. The drug will be marketed under the brand name Vortemyel. Following the launch in Bulgaria, Vortemyel will also be rolled-out across several other Central and Eastern European markets. For the full story, click here.
One Step Ahead for Paraguay
by Gabriela Simancas, FUNCA
The food and drug administration of Paraguay, Dirección de Vigilancia Sanitaria (DINAVISA), is in the process of promulgating a decree to regulate the registration and acceptance of commercialized biotechnological drugs. Such a decree would be considered a milestone for the public health system whose current rules are inadequate to determine if modern complex biological compounds are effective and safe for patients.
The new regulation, created by a committee comprised of physicians from a variety of specialties, is expected to be based on the requirements outlined by the World Health Organization (WHO). This advance in Paraguayan public health will greatly increase patient protection against unsafe and untested drug copies.
The patients and relatives of the patients in Paraguay are hopeful that our country keeps moving down this path that has been started, and we will keep our eyes open to monitor the process.
To submit a news story for publication, please contact
Raymond Wezik, Global Advocacy Executive, International Myeloma Foundation at email@example.com.